Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Tapan M. Kadia, MD
CONTACT
Lead
M.D. Anderson Cancer Center
With
PRIMARY OBJECTIVE: I. To assess safety of patients with acute myeloid leukemia (AML) treated with decitabine and cedazuridine (oral decitabine)-based combinations as maintenance therapy after achieving remission. SECONDARY OBJECTIVES: I. To assess relapse-frees survival (RFS) of patients with AML treated with oral decitabine-based combinations as maintenance therapy. II. To assess overall survival (OS) of patients with AML treated with oral decitabine-based combinations as maintenance therapy. III. To assess event-free survival (EFS) of patients with AML treated with oral decitabine-based combinations as maintenance therapy. IV. To assess the duration of remission (CRd) of patients with AML treated oral decitabine-based combinations as maintenance therapy. V. To assess the effects of oral decitabine-based combinations on dynamics of minimal residual disease and their relationship to outcomes. EXPLORATORY OBJECTIVE: I. To evaluate RFS in (1) intensive induction cohort and (2) lower intensity induction cohort. OUTLINE: Patients are assigned to 1 of 5 arms. ARM A: Patients receive decitabine and cedazuridine orally (PO) once daily (QD) on days 1-3. Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity. ARM C: Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity. ARM D: Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity. ARM E: Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6-12 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
